A detailed history of Charles Schwab Investment Management Inc transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 511,720 shares of NRIX stock, worth $10 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
511,720
Previous 623,404 17.92%
Holding current value
$10 Million
Previous $13 Million 11.7%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$18.93 - $25.69 $2.11 Million - $2.87 Million
-111,684 Reduced 17.92%
511,720 $11.5 Million
Q2 2024

Aug 12, 2024

SELL
$12.02 - $21.3 $225,807 - $400,141
-18,786 Reduced 2.93%
623,404 $13 Million
Q1 2024

May 08, 2024

BUY
$7.77 - $15.66 $154,568 - $311,524
19,893 Added 3.2%
642,190 $9.44 Million
Q4 2023

Feb 06, 2024

BUY
$4.25 - $10.71 $228,314 - $575,351
53,721 Added 9.45%
622,297 $6.42 Million
Q3 2023

Nov 08, 2023

BUY
$7.86 - $10.08 $1.45 Million - $1.86 Million
184,617 Added 48.08%
568,576 $4.47 Million
Q2 2023

Aug 09, 2023

SELL
$8.7 - $13.28 $7,664 - $11,699
-881 Reduced 0.23%
383,959 $3.84 Million
Q1 2023

May 11, 2023

BUY
$8.56 - $13.26 $16,478 - $25,525
1,925 Added 0.5%
384,840 $3.42 Million
Q4 2022

Feb 13, 2023

BUY
$9.86 - $14.59 $82,252 - $121,709
8,342 Added 2.23%
382,915 $4.2 Million
Q3 2022

Nov 14, 2022

BUY
$12.33 - $19.81 $1.04 Million - $1.67 Million
84,114 Added 28.96%
374,573 $4.88 Million
Q2 2022

Aug 15, 2022

BUY
$7.88 - $14.82 $160,783 - $302,387
20,404 Added 7.56%
290,459 $3.68 Million
Q1 2022

May 13, 2022

BUY
$12.94 - $29.65 $83,010 - $190,204
6,415 Added 2.43%
270,055 $3.78 Million
Q4 2021

Feb 11, 2022

BUY
$26.43 - $34.5 $102,548 - $133,860
3,880 Added 1.49%
263,640 $7.63 Million
Q3 2021

Nov 16, 2021

BUY
$22.71 - $36.69 $2.95 Million - $4.77 Million
129,872 Added 99.99%
259,760 $7.78 Million
Q2 2021

Aug 16, 2021

BUY
$24.21 - $35.89 $410,432 - $608,443
16,953 Added 15.01%
129,888 $3.45 Million
Q1 2021

May 17, 2021

BUY
$26.98 - $50.17 $973,006 - $1.81 Million
36,064 Added 46.91%
112,935 $3.51 Million
Q4 2020

Feb 16, 2021

BUY
$22.85 - $48.44 $106,526 - $225,827
4,662 Added 6.46%
76,871 $2.53 Million
Q3 2020

Nov 13, 2020

BUY
$16.05 - $34.91 $1.16 Million - $2.52 Million
72,209 New
72,209 $2.52 Million

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $923M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.